PMCPA

Case examines allegations involving AstraZeneca under the ABPI Code, underscoring the compliance controls drugmakers need to implement.

Ruling reinforces long‑standing Code of Practice expectations on appropriate hospitality, certification, and standards across the pharmaceutical industry.

Actions by Moderna and associated third parties caused concern and ‘reflected poorly on the industry’.

Two cases involving pharmaceutical companies highlight importance of adequate disclosure over payments to healthcare groups.